Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Targeted treatments in endometrial cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.10.11
Views: 9004
Rating:

Dr Helga Salvesen – Haukeland University Hospital, Bergen, Norway

Dr Helga Salvesen talks about the need for endometrial cancer research as it is the most common gynaecological malignancy, but has significantly fewer trials and collected data than that of ovarian and breast cancer despite being so common.

The current treatment is a surgical course after diagnosis and then to classify the patient as high or low risk. From there high risk patients are usually given chemotherapy, with some rare sub groups given radiotherapy. Recent findings have identified promising targets; biomarkers that can identify high and low risk patients, which would allow for high risk patients to receive full treatment including systemic therapy and avoid the overtreatment of low risk patients.

Related videos

follow us

BGICC conference


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation